

Tildrakizumab Biosimilar - Research Grade

Product Code: ICH5303

More Information

Species Reactivity: Human

Target: IL-23A

Concentration: 5mg/ml

Isotype: Human IgG1 (E356D/M358L)-kappa

Host: CHO Cells

product name H2: Tildrakizumab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q9NPF7

Shipping Conditions: Blue ice

background: The IL-23 p19 subunit (IL-23A) defines the IL-23 cytokine that sustains Th17 responses and is a major target in psoriasis and inflammatory bowel disease research. Our research-grade anti-human IL-23A recombinant monoclonal antibody is an unconjugated, non-therapeutic analog of tildrakizumab for research use only (RUO). Manufactured to in vivo standards and purified to low endotoxin, it is available in scalable milligram (mg) to gram (g) quantities for heavy-usage and high-throughput laboratories. It is suited to cytokine neutralization assays, in vitro screening, and in vivo models of autoimmune and inflammatory disease as a reproducible reagent.

Other names: MK-3222,SCH900222,interleukin 23 subunit alpha, IL-23A, IL-23 subunit p19, IL23p19



Specificity: Detects human IL-23A

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.